# Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

> **NCT00118196** · PHASE2 · TERMINATED · sponsor: **Medical University of South Carolina** · enrollment: 1 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** arsenic trioxide
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT00118196
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2006-08-11
- **Final completion:** 2006-08-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to limited resources available to conduct study
- **Last updated:** 2018-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118196, "Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00118196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*